Phio Pharmaceuticals (PHIO) Fireside chat summary

Introduction and agenda

• Audience encouraged to submit questions for the Q&A session at the end of the discussion.

• Focus on updates for PH-762, the INTASYL platform, and its unique mechanism and versatility.

Background and experience of the speaker

• Dr. Jim Cardia joined RXi after a postdoc at Harvard, attracted by the potential of RNAi technology.

• Early work at RXi focused on overcoming delivery challenges for RNAi therapeutics.

• Company shifted from platform discovery to clinical development, then pivoted to immuno-oncology.

Current industry trends

• Immuno-oncology is a major focus due to recent successes with PD-1 antibodies.

• Larger pharmaceutical companies are investing heavily in RNA-based therapeutics.